Promising Phase 1 Data for LB2501 CAR-T Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Clinical Trial Results: In the LB2501 Phase 1 trial, a 100% objective response rate (6/6) was observed in the dose level 2 cohort, with an 83.3% complete response rate (5/6) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, indicating the therapy's potential to transform treatment paradigms.
- Safety Analysis: The therapy showed no dose-limiting toxicities (DLTs) or serious adverse events (SAEs), with all infusion-related reactions being ≤ Grade 2, suggesting a favorable safety profile that may enhance patient acceptance and adherence to treatment.
- CAR-T Cell Expansion: Among 12 patients, dose-dependent in vivo CAR-T cell expansion was observed, with CAR-T cells detectable in peripheral blood for up to 116 days, indicating the therapy's effectiveness and durability, potentially offering long-term therapeutic benefits to patients.
- Innovative Treatment Platform: LB2501 is built on the TaVec™ platform, designed to generate CAR-T cells directly within the patient following a single intravenous infusion, simplifying treatment delivery and expanding access for patients who may not be eligible for traditional CAR-T therapies, which holds significant strategic implications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.200
Low
48.00
Averages
68.10
High
90.00
Current: 34.200
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Legend Biotech's LB2501 Shows Promising Data for Lymphoma Treatment
- Clinical Trial Results: Legend Biotech's LB2501 demonstrated promising preliminary data in treating B-cell non-Hodgkin lymphoma, achieving a 100% objective response rate and an 83.3% complete response rate among 12 patients, indicating significant efficacy that could transform treatment paradigms for B-cell malignancies.
- Strong Market Reaction: Following the data release, LEGN's stock surged over 42% on Tuesday, closing at $36.28, reflecting investor confidence in the therapy's prospects and highlighting the market's keen interest in biopharmaceutical innovations.
- Innovative Treatment Mechanism: LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T cell therapy that generates CAR-T cells through a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, which may enhance patient convenience and acceptance of the treatment.
- Good Safety Profile: In the ongoing open-label Phase 1 study, no dose-limiting toxicities or serious adverse events were reported, and while 75% of patients experienced infusion-related reactions, all were recorded at Grade 2 severity or lower, demonstrating LB2501's favorable safety profile and enhancing its clinical applicability.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Promising Phase 1 Data for LB2501 CAR-T Therapy
- Clinical Trial Results: In the LB2501 Phase 1 trial, a 100% objective response rate (6/6) was observed in the dose level 2 cohort, with an 83.3% complete response rate (5/6) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, indicating the therapy's potential to transform treatment paradigms.
- Safety Analysis: The therapy showed no dose-limiting toxicities (DLTs) or serious adverse events (SAEs), with all infusion-related reactions being ≤ Grade 2, suggesting a favorable safety profile that may enhance patient acceptance and adherence to treatment.
- CAR-T Cell Expansion: Among 12 patients, dose-dependent in vivo CAR-T cell expansion was observed, with CAR-T cells detectable in peripheral blood for up to 116 days, indicating the therapy's effectiveness and durability, potentially offering long-term therapeutic benefits to patients.
- Innovative Treatment Platform: LB2501 is built on the TaVec™ platform, designed to generate CAR-T cells directly within the patient following a single intravenous infusion, simplifying treatment delivery and expanding access for patients who may not be eligible for traditional CAR-T therapies, which holds significant strategic implications.
See More
Legend Biotech Announces Phase 1 Results for LB2102 in Lung Cancer
- Clinical Trial Progress: Legend Biotech presented Phase 1 trial results for LB2102 at the 2026 ASCO annual meeting, revealing an objective response rate (ORR) of 28.6% and a disease control rate (DCR) of 78.6% at higher doses, offering new hope for treating small cell lung cancer and large cell neuroendocrine carcinoma.
- Efficacy Data: The overall ORR was 20% with a DCR of 70%, while the median duration of disease control was 6.1 months and the median duration of response was 6.5 months, indicating the therapy's potential clinical value in disease management.
- Safety Assessment: Adverse events were minimal, with at least 30% of patients experiencing cytokine release syndrome (CRS) and 15% experiencing immune effector cell-associated neurotoxicity syndrome (ICANS), with no dose-limiting toxicities or treatment-related deaths reported, highlighting the therapy's safety profile.
- Market Performance: Despite LEGN closing at $25.51, down 6.08%, the stock rebounded to $26.23 in the overnight market, up 2.82%, reflecting investor interest and confidence in the new therapy.
See More
LB2102 Shows Promising Clinical Activity in Small Cell Lung Cancer Trials
- Initial Clinical Activity: LB2102 demonstrates an objective response rate (ORR) of 28.6% and a disease control rate (DCR) of 78.6% in patients with small cell lung cancer, indicating its potential efficacy in heavily pretreated populations, which may provide new hope for patients with limited treatment options.
- Safety Profile: The clinical trial of LB2102 reported no dose-limiting toxicities or treatment-related deaths, with 30% of patients experiencing cytokine release syndrome (CRS) at Grade ≤2, showcasing the therapy's manageable safety profile, which could facilitate its further application in solid tumors.
- CARVYKTI® Sustained Efficacy: New analyses reveal that CARVYKTI® continues to show significant clinical benefits in multiple myeloma patients, with over 85% overall survival rates at 30 months, reinforcing its position as a transformative therapy and enhancing the company's leadership in cell therapy.
- Strategic Expansion: The development of LB2102 is part of Legend Biotech's strategy to extend CAR-T therapies into solid tumors, coupled with a licensing agreement with Novartis, potentially laying the groundwork for future growth and market share enhancement.
See More
Legend Biotech Presents Preliminary Data for LB2102 at ASCO Meeting
- Preliminary Data Presentation: Legend Biotech showcased preliminary Phase 1 data for LB2102 at the 2026 ASCO Annual Meeting, indicating clinical activity in relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, suggesting the potential for CAR-T therapies to expand into solid tumors, which could open new market opportunities for the company.
- New CARVYKTI Data: The company also presented new data on CARVYKTI® at ASCO, further supporting its efficacy and safety profile in patients with multiple myeloma, enhancing its competitive position in the market and potentially driving sales growth.
- Impact of Licensing Agreement: The exclusive global licensing agreement with Novartis grants them rights to develop and commercialize DLL3-targeted CAR-T therapies, marking a strategic expansion for the company in the CAR-T space, which could lead to significant revenue streams.
- Investor Relations Event: Legend Biotech will host an investor relations event during the ASCO meeting featuring clinician experts discussing how CARVYKTI® is transforming the treatment landscape for multiple myeloma, which is expected to boost investor confidence and attract more attention.
See More
Legend Biotech's LB2501 Shows Promising Data for Lymphoma Treatment
- Clinical Trial Results: Legend Biotech's LB2501 demonstrated promising preliminary data in treating B-cell non-Hodgkin lymphoma, achieving a 100% objective response rate and an 83.3% complete response rate among 12 patients, indicating significant efficacy that could transform treatment paradigms for B-cell malignancies.
- Strong Market Reaction: Following the data release, LEGN's stock surged over 42% on Tuesday, closing at $36.28, reflecting investor confidence in the therapy's prospects and highlighting the market's keen interest in biopharmaceutical innovations.
- Innovative Treatment Mechanism: LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T cell therapy that generates CAR-T cells through a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, which may enhance patient convenience and acceptance of the treatment.
- Good Safety Profile: In the ongoing open-label Phase 1 study, no dose-limiting toxicities or serious adverse events were reported, and while 75% of patients experienced infusion-related reactions, all were recorded at Grade 2 severity or lower, demonstrating LB2501's favorable safety profile and enhancing its clinical applicability.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Promising Phase 1 Data for LB2501 CAR-T Therapy
- Clinical Trial Results: In the LB2501 Phase 1 trial, a 100% objective response rate (6/6) was observed in the dose level 2 cohort, with an 83.3% complete response rate (5/6) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, indicating the therapy's potential to transform treatment paradigms.
- Safety Analysis: The therapy showed no dose-limiting toxicities (DLTs) or serious adverse events (SAEs), with all infusion-related reactions being ≤ Grade 2, suggesting a favorable safety profile that may enhance patient acceptance and adherence to treatment.
- CAR-T Cell Expansion: Among 12 patients, dose-dependent in vivo CAR-T cell expansion was observed, with CAR-T cells detectable in peripheral blood for up to 116 days, indicating the therapy's effectiveness and durability, potentially offering long-term therapeutic benefits to patients.
- Innovative Treatment Platform: LB2501 is built on the TaVec™ platform, designed to generate CAR-T cells directly within the patient following a single intravenous infusion, simplifying treatment delivery and expanding access for patients who may not be eligible for traditional CAR-T therapies, which holds significant strategic implications.
See More
Legend Biotech Announces Phase 1 Results for LB2102 in Lung Cancer
- Clinical Trial Progress: Legend Biotech presented Phase 1 trial results for LB2102 at the 2026 ASCO annual meeting, revealing an objective response rate (ORR) of 28.6% and a disease control rate (DCR) of 78.6% at higher doses, offering new hope for treating small cell lung cancer and large cell neuroendocrine carcinoma.
- Efficacy Data: The overall ORR was 20% with a DCR of 70%, while the median duration of disease control was 6.1 months and the median duration of response was 6.5 months, indicating the therapy's potential clinical value in disease management.
- Safety Assessment: Adverse events were minimal, with at least 30% of patients experiencing cytokine release syndrome (CRS) and 15% experiencing immune effector cell-associated neurotoxicity syndrome (ICANS), with no dose-limiting toxicities or treatment-related deaths reported, highlighting the therapy's safety profile.
- Market Performance: Despite LEGN closing at $25.51, down 6.08%, the stock rebounded to $26.23 in the overnight market, up 2.82%, reflecting investor interest and confidence in the new therapy.
See More
LB2102 Shows Promising Clinical Activity in Small Cell Lung Cancer Trials
- Initial Clinical Activity: LB2102 demonstrates an objective response rate (ORR) of 28.6% and a disease control rate (DCR) of 78.6% in patients with small cell lung cancer, indicating its potential efficacy in heavily pretreated populations, which may provide new hope for patients with limited treatment options.
- Safety Profile: The clinical trial of LB2102 reported no dose-limiting toxicities or treatment-related deaths, with 30% of patients experiencing cytokine release syndrome (CRS) at Grade ≤2, showcasing the therapy's manageable safety profile, which could facilitate its further application in solid tumors.
- CARVYKTI® Sustained Efficacy: New analyses reveal that CARVYKTI® continues to show significant clinical benefits in multiple myeloma patients, with over 85% overall survival rates at 30 months, reinforcing its position as a transformative therapy and enhancing the company's leadership in cell therapy.
- Strategic Expansion: The development of LB2102 is part of Legend Biotech's strategy to extend CAR-T therapies into solid tumors, coupled with a licensing agreement with Novartis, potentially laying the groundwork for future growth and market share enhancement.
See More
Legend Biotech Presents Preliminary Data for LB2102 at ASCO Meeting
- Preliminary Data Presentation: Legend Biotech showcased preliminary Phase 1 data for LB2102 at the 2026 ASCO Annual Meeting, indicating clinical activity in relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma, suggesting the potential for CAR-T therapies to expand into solid tumors, which could open new market opportunities for the company.
- New CARVYKTI Data: The company also presented new data on CARVYKTI® at ASCO, further supporting its efficacy and safety profile in patients with multiple myeloma, enhancing its competitive position in the market and potentially driving sales growth.
- Impact of Licensing Agreement: The exclusive global licensing agreement with Novartis grants them rights to develop and commercialize DLL3-targeted CAR-T therapies, marking a strategic expansion for the company in the CAR-T space, which could lead to significant revenue streams.
- Investor Relations Event: Legend Biotech will host an investor relations event during the ASCO meeting featuring clinician experts discussing how CARVYKTI® is transforming the treatment landscape for multiple myeloma, which is expected to boost investor confidence and attract more attention.
See More
